Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?

NTLA received FDA priority review for lonvo-z, with a regulatory decision expected March 10, 2027, potentially positioning the therapy as the company’s first commercial product. The company also said nex-z studies are progressing well, supporting continued pipeline momentum. The priority-review designation is a positive regulatory catalyst but approval remains pending.